Cargando…

Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma

BACKGROUND: Invariant natural killer T (iNKT) cells are a small population of lymphocytes with unique specificity for glycolipid antigens presented by non-polymorphic CD1d receptor on dendritic cells (DCs). iNKT cells play a central role in tumor immunology since they are implicated in the coordinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escribà-Garcia, Laura, Alvarez-Fernández, Carmen, Tellez-Gabriel, Marta, Sierra, Jorge, Briones, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446707/ https://www.ncbi.nlm.nih.gov/pubmed/28549432 http://dx.doi.org/10.1186/s12967-017-1219-3

Ejemplares similares

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
por: Shimizu, Kanako, et al.
Publicado: (2007)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
por: Alvarez‐Fernández, Carmen, et al.
Publicado: (2021)

Tumor-infiltrating effector cells of α-galactosylceramide-induced antitumor immunity in metastatic liver tumor
por: Osada, Takuya, et al.
Publicado: (2004)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
por: Caballero, Ana Carolina, et al.
Publicado: (2022)

Soluble and Exosome-Bound α-Galactosylceramide Mediate Preferential Proliferation of Educated NK Cells with Increased Anti-Tumor Capacity
por: Wagner, Arnika K., et al.
Publicado: (2021)

Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
por: Adam, Christian, et al.
Publicado: (2007)

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141(+) Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8(+) T Cell Response in Human Immune System Mice
por: Huang, Jing, et al.
Publicado: (2020)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

An unusual case of metachronous NK/T cell lymphoma and interdigitating dendritic cell sarcoma
por: Hwang, So Yeon, et al.
Publicado: (2017)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

LIR‐1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody‐dependent cellular cytotoxicity
por: Leijonhufvud, Caroline, et al.
Publicado: (2021)

NK-/T-cell lymphomas
por: Wang, Hua, et al.
Publicado: (2021)

Silent T-cell receptor cutaneous T-cell lymphoma associated to a clonal plasma cell proliferation
por: Caballero, Ana, et al.
Publicado: (2019)

The CD85j(+) NK Cell Subset Potently Controls HIV-1 Replication in Autologous Dendritic Cells
por: Scott-Algara, Daniel, et al.
Publicado: (2008)

Harnessing novel engineered feeder cells expressing activating molecules for optimal expansion of NK cells with potent antitumor activity
por: Min, Bokyung, et al.
Publicado: (2021)

Allogeneic dendritic cells induce potent antitumor immunity by activating KLRG1(+)CD8 T cells
por: Wang, Chao, et al.
Publicado: (2019)

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
por: Kitamura, Hidemitsu, et al.
Publicado: (1999)

NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy?
por: Vacca, Paola, et al.
Publicado: (2013)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Suppression of murine tumour growth through CD8(+) cytotoxic T lymphocytes via activated DEC‐205(+) dendritic cells by sequential administration of α‐galactosylceramide in vivo
por: Kogo, Hideki, et al.
Publicado: (2017)

Diversity of Epigenetic Features of the Inactive X-Chromosome in NK Cells, Dendritic Cells, and Macrophages
por: Syrett, Camille M., et al.
Publicado: (2019)

Extranodal NK/T cell lymphoma
por: Jeong, Seong Hyun
Publicado: (2020)

Extranodal T- and NK-cell lymphomas
por: de Leval, Laurence, et al.
Publicado: (2022)

DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice
por: Cao, Jun, et al.
Publicado: (2013)

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
por: Fujii, Shin-ichiro, et al.
Publicado: (2003)

The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines
por: Liu, Yonghui, et al.
Publicado: (2021)

In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma
por: Kikuchi, A, et al.
Publicado: (2001)

The Molecular Basis for Recognition of CD1d/α-Galactosylceramide by a Human Non-Vα24 T Cell Receptor
por: López-Sagaseta, Jacinto, et al.
Publicado: (2012)

A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy
por: Alvarez-Fernández, C., et al.
Publicado: (2016)

Structure and binding kinetics of three different human CD1d–α-galactosylceramide–specific T cell receptors
por: Gadola, Stephan D., et al.
Publicado: (2006)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

α-Galactosylceramide Analogs with Weak Agonist Activity for Human iNKT Cells Define New Candidate Anti-Inflammatory Agents
por: Bricard, Gabriel, et al.
Publicado: (2010)

Dendritic cells loaded with CD44(+) CT-26 colon cell lysate evoke potent antitumor immune responses
por: Fu, Changhao, et al.
Publicado: (2019)

Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer
por: Toyoda, Takahide, et al.
Publicado: (2020)

An autopsy case of primary extranodal NK/T cell lymphoma (extranodal NK/T-cell lymphoma) of the bile duct
por: Ito, Hiroyuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rd1jms0dtng4qkpjojjrnaurm8